Background. In a small radioligand-binding study of cutaneous α 1 -adrenoceptors in
Introduction
Complex regional pain syndrome (CRPS) is an intriguing condition with many paradoxes (1, 2) . Early descriptions of soldiers with traumatic limb injuries included signs of autonomic disturbance such as excessive sweating, oedema, temperature asymmetry and altered skin blood flow (3) . During World War I and later conflicts, successful treatment of CRPS type II (causalgia) with surgical sympathectomy furthered the concept of sympathetic nervous system involvement (4, 5) . Similar disturbances of autonomic function were also seen after non-combat injuries, and the term "reflex sympathetic dystrophy" (CRPS type I) was coined (6) . However, sympatholytic interventions provided pain relief in only a minority of cases (7, 8) . The subgroup that did respond to sympatholysis was deemed to have "sympathetically maintained" pain but the mechanism by which this could occur was unclear. In this subgroup, sympathetic blockade reduced pain and mechanical hyperalgesia that could be rekindled by the application of noradrenaline and other adrenergic agonists (9) (10) (11) , suggesting that pain might be driven by excessive efferent sympathetic activity. However, this became less attractive as a pathophysiological mechanism for the development of CRPS when evidence to the contrary appeared. Specifically, concentrations of noradrenaline and its metabolite 3,4-dihydroxyphenylethyleneglycol were found to be lower in the affected than contralateral unaffected limb in patients with CRPS, indicating that sympathetic outflow might be compromised (12, 13) . Afferent sensory-sympathetic coupling has been suggested as a mechanism for the development of sympathetically maintained pain (14, 15) but, again, evidence for this is sparse (16) .
Instead, α-adrenoceptor supersensitivity might, in part, explain some of the clinical findings in CRPS (17, 18) . A search for evidence of up-regulation of cutaneous adrenoceptors (α 1 -ARs) led us to study their density in skin biopsies taken from normal individuals and in patients suffering from CRPS using a selective radioligand (19) . The findings indicated an increase in receptor density in CRPS-affected skin; however, a more refined technique was required to determine the distribution of α 1 -ARs in skin organelles, keratinocytes and especially nerve fibres. In a subsequent animal study, immunohistochemistry was used to determine the expression of α 1 -AR on primary nociceptive afferents that innervated the healthy skin of adult Wistar rats. α 1 -ARs were found to co-localise with nociceptive markers in cutaneous nerve fibres, providing a possible means of excitation of these fibres by adrenergic agonists (20) . We reported recently that α 1 -ARs were expressed more strongly on keratinocytes and nociceptive afferents in the ipsilateral than contralateral plantar hind paw of rats after chronic constriction injury of the sciatic nerve (a model of CRPS type II) (21) . Similarly, in the partial sciatic nerve ligation model, α 1 -ARs were expressed more strongly on nociceptive afferents in the sciatic nerve trunk and distal skin 4 and 28 days after injury than after sham surgery (22) . Furthermore, α 1 -AR expression was greater on dermal nerve fibres and keratinocytes in the affected than contralateral unaffected limb of patients who had developed CRPS type II after peripheral nerve trauma.
The purpose of the current study was to investigate the expression of α 1 -ARs in the skin of healthy volunteers and patients suffering from CRPS without signs of major nerve trauma (CRPS type I). As symptoms of CRPS type I are similar to those of CRPS type II, we hypothesized that these patients would have greater expression of cutaneous α 1 -ARs than healthy volunteers and, in particular, increased numbers in specific structures such as neurons, keratinocytes, blood vessels and sweat glands. Up-regulation of α 1 -ARs on these cells would provide evidence in support of an involvement of α 1 -ARs in the pathophysiology of CRPS type I (14, 23) .
Methods

Participants
Skin samples were obtained from eight men and 23 women aged between 20 and 68 years (mean age ± S.D. 41 ± 12 years) with CRPS type I in an upper or lower limb, and from 10 men and 13 women aged between 20 and 68 years (mean age 34 ± 16 years) from the university population who were free of pain. Each participant provided written informed consent for the procedures, which were approved by the institutional ethics committee.
Procedures
Each patient was reviewed by a pain physician to determine whether clinical criteria for CRPS type I were met. The syndrome began after a limb fracture (seven cases) or soft-tissue injury without obvious major nerve trunk involvement (22 cases), or started after no identifiable cause (two cases). In each case, pain and other symptoms spread beyond the injured area, sometimes to another limb, but involved the contralateral side in only three cases (one with reduction in sensation in the contralateral thigh, and another two with mild contralateral symptoms and pain). Patients with prominent bilateral symptoms were excluded. Patients provided a rating of mean pain intensity over the two weeks prior to examination on a visual analogue scale. They were also questioned about present or past sensory and autonomic disturbances in the affected limb, movement deficits and trophic changes in the hair, nails and skin. During the examination the following signs were graded as absent, mild or severe: allodynia to briskly tapping the limb with a finger and sensory blunting to painfully scratching the skin with the sharp end of a paperclip; swelling; and motor disturbances such as decreased range of movement, weakness and tremor. In addition, trophic signs and autonomic disturbances were noted.
CRPS was considered to be present when reports of sensory, and/or autonomic and/or motor disturbances were substantiated in the clinical examination, as specified in the Budapest clinical diagnostic criteria for CRPS type I (24).
Skin samples were obtained under sterile conditions from a site of mechanical or thermal hyperalgesia (generally the dorso-lateral aspect of the affected hand or foot) using a 3 mm diameter skin biopsy punch under local anaesthesia. Samples from a mirror image pain-free site on the contralateral side of the body were also obtained. In controls, skin samples were obtained from the dorso-lateral aspect of one hand or the ventral forearm.
Healing was uneventful in each case.
Tissue preparation and immunohistochemistry
Skin samples were fixed in Zamboni's solution (5% formalin and 1% picric acid Table 1 . In addition, two consecutive sections from the same biopsy were labelled concurrently on the same slide to check the reproducibility of staining.
To localise α 1 -AR expression on blood vessels and the secretory coil of sweat glands, sections were double labelled with antibodies against α 1 -AR and smooth muscle actin (SMA). Sections were treated with 0.2% Triton X-100 diluted in PBS for 5 min and pre-incubated for 2 h in a blocking solution containing PBS, 0.1% sodium azide and 10% normal donkey serum (Sigma-Aldrich) at room temperature. Sections were then incubated with primary antibodies (Table 1 ) diluted in blocking solution for 48 h in a humidified chamber at 4 °C. Sections were washed in three changes of PBS for 15 min at room temperature and incubated with species-specific secondary antibodies (Table 1) diluted in PBS containing 0.1% sodium azide and 5% normal donkey serum for 4 h at room temperature. Sections were washed in three changes of PBS for 15 min at room temperature and mounted with Prolong Gold antifade mounting reagent (Invitrogen, Victoria, Australia).
To examine α 1 -AR expression on nerve fibres, the tyramide signal amplification (TSA) method was used (25) , allowing differentiation between primary antibodies raised in the same species. In these studies a biotin-conjugated TSA kit (NEL700; Perkin-Elmer Life Sciences, Victoria, Australia) was used to detect the pan-neuronal rabbit anti-PGP9.5 primary antibody, which was used at such a dilute concentration (1:400,000) that only TSA permitted subsequent detection. The second rabbit primary antibody against α 1 -AR was used at normal concentration (1:250) and was detected by conventional immunohistochemistry. Endogenous peroxidase activity of tissue sections was quenched by incubation in 3% H 2 O 2 in PBS for 10 min prior to application of blocking solution.
Skin sections were incubated with the first primary antibody (anti-PGP9.5) overnight at room temperature in blocking solution. Sections were then consecutively incubated with biotin-conjugated donkey anti-rabbit IgG for 1 h (1:1000; Jackson ImmunoResearch, PA, USA), streptavidin-horse radish peroxidase in PBS for 30 min (1:150) followed by biotinconjugated tyramide diluted 1:100 in amplification solution for 3 min. Visualisation was achieved using DyLight 549-conjugated streptavidin (diluted 1:1000 in PBS, 1 h; Jackson ImmunoResearch, PA, USA). Between subsequent steps, sections were washed in three changes of PBS for 15 min.
Experimental controls
Controls for the specificity of the antibodies used in this study have been documented previously (20, 26, 27) . To control for cross-reactivity between secondary antibodies, the procedures were performed as listed above except that one or other of the Quantification of α 1 -AR expression in skin α 1 -AR expression was quantified in the epidermis, sweat glands, blood vessels and nerve fibres by an investigator (ESD) who was blinded to side and group. Sweat glands and blood vessels were identified by SMA immunoreactivity, and nerve fibres were identified by PGP9.5 immunoreactivity. The epidermis was identified by morphology. Immunostained skin sections were imaged using a Leica TCS SP2 multiphoton confocal microscope. Two 200X magnification confocal image stacks were collected per section: one image of the papillary dermis and one image of the reticular dermis. Images were collected using identical laser power, gain and offset settings and each channel was imaged in a sequential manner to prevent overlap of emission spectra.
Quantification was carried out using ImageJ image processing and analysis software (http://rsbweb.nih.gov/ij/), and was performed on the maximum projection of each confocal image stack. α 1 -AR expression was measured as the average pixel intensity in a region of interest and was quantified in three sweat glands and all cross-sectional blood vessels in each image. α 1 -AR staining intensity was also measured on nerve fibres in nerve bundles by creating a mask of PGP9.5 immunostaining in ImageJ, ensuring that consequent α 1 -AR expression was examined only in those pixels that were also positive for PGP9.5 ( Figure 1 ). Quantification of α 1 -AR expression in the epidermis was performed by manually drawing around the epidermis and measuring the average α 1 -AR staining intensity in the defined region.
Statistical approach
To permit data to be combined across multiple immunohistochemistry runs, α 1 -AR + pixel intensity for each sample in each region of interest (the epidermis, sweat glands, blood vessels and dermal nerve fibres) was normalised within each run by expressing it as a z-score (i.e., with a mean of 0 and a standard deviation of 1).
Preliminary analyses indicated that α 1 -AR staining intensity was similar in the upper and lower limbs both on the affected and unaffected side of patients with CRPS; thus, data for all patients were pooled. Differences in α 1 -AR staining intensity between patients and controls were investigated with the Mann-Whitney U test, and differences between CRPS-affected and contralateral limbs were examined with Wilcoxon's matched-pairs signed-rank test. Associations between α 1 -AR immunoreactivity in the affected limb and CRPS duration, present pain intensity and symptom intensity were explored with Kendall's tau-b correlation coefficient. For these analyses, a pain rating of 1-3 was coded as "mild", 4-6 as "moderate" and 7-10 as "severe". In addition, CRPS for 6 months or less was coded as "acute", and longer than 6 months as "chronic".
Results
The majority of patients had suffered CRPS for extended periods (up to 230 months, mean 51 ± 57 months) but in six cases it had been present for six months or less.
Pain intensity and symptoms associated with CRPS are listed in Table 2 . Sympathetic blocks were administered once to eight patients and were administered two or more times to another six patients. In three of these patients, sympathetic blockade with onabotulinumtoxinA or radiofrequency lesions was followed by prolonged decreases in pain.
The localisation of α 1 -ARs in the skin of humans was comparable to that described previously in animal tissues (20) , with the receptors evident on blood vessels, sweat glands, keratinocytes and nerve fibres (Figures 1 and 2 ). α 1 -AR staining was observed on nerve fibres in the papillary dermis in close proximity to the epidermaldermal border, on fibres surrounding sweat glands in the reticular dermis and on fibres and the perineurium in nerve bundles (Figure 1 ). (Table 3) , and there was no clear difference in α 1 -AR staining intensity between the three patients who obtained prolonged benefits from sympathetic blockade and the other patients. In addition, there was no association between CRPS symptoms and α 1 -AR staining intensity in the contralateral limb.
Discussion
We reported recently that α 1 -ARs were expressed more strongly on nociceptive fibres in the affected than contralateral hind paw of rats after partial sciatic nerve ligation and chronic constriction injury (21, 22) , and were expressed more strongly on nerve fibres and keratinocytes in the affected than contralateral unaffected limb of patients with CRPS type II (22) . Thus, of particular note in the present study was the heightened The distribution of α 1 -ARs on dermal blood vessels was similar in patients and controls. Spontaneous pain and mechanical hyperalgesia intensify during whole body cooling in CRPS patients with "sympathetically maintained pain" (62) , possibly due to microvascular pathology that produces ischaemia and inflammation (23, 63, 64) . In patients with CRPS, constriction of superficial hand veins to infusion of noradrenaline is greater than normal, consistent with heightened vascular expression of α-adrenoceptors (65) . However, in the present study, the distribution of α 1 -ARs on dermal blood vessels was similar in patients and controls. It would be of interest in future studies to assess whether the distribution of α 1 -ARs on dermal blood vessels and other cellular targets is altered in patients with signs of sympathetically maintained pain (i.e., those who benefit from sympathetic blockade or whose pain responds to intradermal injection of adrenergic agents). Unfortunately, this could not be examined in the present study, as only a few patients clearly benefited from sympathetic blockade.
In the present study, α 1 -AR staining intensity was similar in the sweat glands of patients and controls. It has been shown that axon-reflex sweating to iontophoresis of the α 1 -AR agonist phenylephrine was greater in the affected limb of patients with acute CRPS type I compared to controls and patients who had recovered from CRPS (66) .
While this suggests that a heightened α 1 -AR expression on sudomotor nerve fibres or the sweat glands themselves might drive hyperhidrosis, we were unable to explore this as sweating was not investigated quantitatively in our study.
Some additional limitations apply to this study. For example, one-quarter of the patients rated pain as mild during the two weeks prior to the skin biopsy, and the majority had pain for longer than six months. As sympathetically maintained pain appears to be more common in the acute than chronic stages of CRPS (11), α 1 -AR staining intensity might also be greater in patients with acute than chronic pain. In most of our patients, symptoms were confined to the injured limb. However, we may have overlooked subclinical contralateral disturbances associated with α 1 -AR up-regulation. Quantitative sensory and physiological studies involving comparisons with healthy controls will be required to resolve this. Finally, α 1 -AR staining was investigated in the epidermis as a whole, based on morphology. Although most cells in the epidermis are keratinocytes, in future studies it would be important to identify these cells with specific markers of keratin.
In conclusion, α 1 -ARs were up-regulated bilaterally in the dermal nerves and keratinocytes of patients with CRPS type I. This heightened α 1 -AR expression might increase vulnerability to CRPS type I and/or contribute to neuroinflammatory disturbances and pain by augmenting the excitability of these cells. If so, topical treatments that target up-regulated α 1 -ARs could be beneficial in relieving allodynia and pain in patients with CRPS type I. 
